EcoDrugPlus

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSBTAG00000031358
Gene Symbol: DPYD
4 Enzyme and pathways 5 Cross references
242 Possible Orthologues:

Dipeptidyl Peptidase 4

Ensembl ID : ENSBTAG00000048246
Gene Symbol: DPP4
5 Enzyme and pathways 5 Cross references
298 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSBTAG00000004885
Gene Symbol: DDR2
2 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSBTAG00000047719
Gene Symbol: DRD1
8 Enzyme and pathways 5 Cross references
274 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSBTAG00000010860
Gene Symbol: DRD2
6 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSBTAG00000002132
Gene Symbol: DRD3
8 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSBTAG00000051042
Gene Symbol: DRD4
5 Cross references
255 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSBTAG00000038606
Gene Symbol: DRD5
8 Enzyme and pathways 5 Cross references
175 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSBTAG00000013165
Gene Symbol: ENPP2
5 Cross references
240 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSBTAG00000053296
Gene Symbol: EGLN1
4 Enzyme and pathways 5 Cross references
251 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSBTAG00000017996
Gene Symbol: EGLN2
4 Enzyme and pathways 5 Cross references
206 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSBTAG00000008172
Gene Symbol: EGLN3
4 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).